Update results of paclitaxel and cisplatin in combination with anlotinib as first-line treatment for patients with advanced ESCC: A multicenter, single-arm, open-label phase II clinical trial

被引：0
|
作者：
Wang, J. [1 ]
Wu, T. [1 ]
Hong, Y-G. [1 ]
Luo, S-X. [2 ]
Li, N. [2 ]
Guo, Y-Z. [3 ]
Cheng, Y-F. [4 ]
机构：
[1] Anyang Tumour Hosp, Med Oncol Dept, Anyang, Peoples R China
[2] Henan Canc Hosp, Med Oncol Dept, Zhengzhou, Peoples R China
[3] Henan Univ Sci & Technol, Affiliated Hosp 1, Med Oncol Dept, Luoyang, Peoples R China
[4] Shandong Univ, Qilu Hosp, Med Oncol Dept, Jinan, Peoples R China
来源：
ANNALS OF ONCOLOGY | 2021年 / 32卷
关键词：
D O I：
10.1016/j.annonc.2021.08.1513
中图分类号：
R73 [肿瘤学];
学科分类号：
100214 ;
摘要：
1404P
引用
收藏
页码：S1058 / S1058
页数：1
相关论文
共 50 条
  • [21] Tislelizumab in combination with anlotinib as first-line treatment for unresectable hepatocellular carcinoma: A single-arm, phase II clinical trial.
    Laoguo, Shi-xue
    Huang, Huasheng
    Zeng, Jie
    Jiang, Yangfeng
    Liu, Cuizhen
    Mo, Ning
    Zhu, GuangZhi
    Ma, Fuchao
    Peng, Tao
    Zeng, Zhiming
    Ma, Jie
    JOURNAL OF CLINICAL ONCOLOGY, 2023, 41 : 576 - 576
  • [22] Anlotinib combined with TQB2450 (PD-L1 blockade) as first-line treatment for advanced esophageal squamous cell carcinoma (ESCC): A single-arm, multicenter, open-label phase. clinical trial.
    Yang, Xiuli
    Meng, Xiangrui
    Hong, Yong-Gui
    Zhang, Zhiye
    Xia, Jin
    Wu, Tao
    Chen, Yunfang
    Shan, Zheng-Zheng
    Fan, Qingxia
    Wang, Feng
    JOURNAL OF CLINICAL ONCOLOGY, 2023, 41 : 377 - 377
  • [23] Surufatinib in combination with toripalimab in patients with advanced neuroendocrine carcinoma: Results from a multicenter, open-label, single-arm, phase II trial.
    Shen, Lin
    Yu, Xianjun
    Lu, Ming
    Zhang, Xing
    Cheng, Ying
    Zhang, Yanqiao
    Li, Zhiping
    Xu, Jianming
    Weng, Desheng
    Wu, Chunjiao
    Ma, Yue
    Cheng, Ke
    Wang, Wenquan
    Gao, Heli
    Li, Yi
    Zhou, Jinghong
    Shi, Haiyan
    Tan, Panfeng
    Su, Weiguo
    JOURNAL OF CLINICAL ONCOLOGY, 2021, 39 (15)
  • [24] Anlotinib in Chinese Patients With Recurrent Advanced Cervical Cancer: A Prospective Single-Arm, Open-Label Phase II Trial
    Zhu, Jun
    Song, Chunyan
    Zheng, Zhong
    Xia, Lingfang
    Chen, Yanqiong
    Ke, Guihao
    Wu, Xiaohua
    FRONTIERS IN ONCOLOGY, 2021, 11
  • [25] Anlotinib plus sintilimab in patients with recurrent advanced endometrial cancer: A prospective open-label, single-arm, phase II clinical trial
    Wei, W.
    Ban, X.
    Yang, F.
    Huang, Y.
    Li, J.
    Cheng, X.
    Zheng, M.
    Li, J.
    ANNALS OF ONCOLOGY, 2021, 32 : S762 - S762
  • [26] Toripalimab with nab-paclitaxel/gemcitabine as first-line treatment for advanced pancreatic adenocarcinoma: Updated results of a single-arm, open-label, phase Ib/II clinical study.
    Cheng, Ke
    Lv, Wan-Rui
    Li, Xiaofen
    Tian, Bole
    Cao, Dan
    JOURNAL OF CLINICAL ONCOLOGY, 2021, 39 (15)
  • [27] SUCCINCT: An Open-label, Single-arm, Non-randomised, Phase 2 Trial of Gemcitabine and Cisplatin Chemotherapy in Combination with Sunitinib as First-line Treatment for Patients with Advanced Urothelial Carcinoma
    Geldart, Thomas
    Chester, John
    Casbard, Angela
    Crabb, Simon
    Elliott, Tony
    Protheroe, Andrew
    Huddart, Robert A.
    Mead, Graham
    Barber, Jim
    Jones, Robert J.
    Smith, Joanna
    Cowles, Robert
    Evans, Jessica
    Griffiths, Gareth
    EUROPEAN UROLOGY, 2015, 67 (04) : 599 - 602
  • [28] Sintilimab in combination with anlotinib in advanced NSCLC treated with first-line PD-1 antibodies: An open, single-arm, phase II trial
    Jin, Y.
    Yu, X.
    Fan, Y.
    He, X. Q.
    Lin, C.
    Hong, W.
    Gu, C.
    ANNALS OF ONCOLOGY, 2023, 34 : S1656 - S1657
  • [29] A phase II single-arm study of pazopanib and paclitaxel as first-line treatment for patients with advanced melanoma
    Fruehauf, John P.
    Alger, Beverly
    Jakowatz, James G.
    Hsiang, David
    Sender, Leonard S.
    Bettis, Claudette
    Casey, Cameron
    JOURNAL OF CLINICAL ONCOLOGY, 2014, 32 (15)
  • [30] Anlotinib plus sintilimab in patients with recurrent advanced endometrial cancer: A prospective open-label, single-arm, phase II clinical trial.
    Wei, Wei
    Ban, Xiaohua
    Yang, Fan
    Huang, Yongwen
    Li, Jibin
    Qiu, Ya
    Cheng, Xiaqin
    Li, Jundong
    Zheng, Min
    JOURNAL OF CLINICAL ONCOLOGY, 2021, 39 (15)
12345